FOLH1 and prostate cancer: Biochemical response defined by PCWG3 (Prostate Cancer Working Group 3) as ≥ 50% decrease of baseline PSA serum level [18] occurs in 30–65% of patients undergoing [177Lu]Lu-PSMA RLT [19], although, in some cases, it may only appear after several cycles of therapy [20].